Drugs and patents in ATC class P01BB

Subscribe to access the full database, or Get Started Free
Tradename	Generic Name
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE	atovaquone; proguanil hydrochloride
MALARONE	atovaquone; proguanil hydrochloride
MALARONE PEDIATRIC	atovaquone; proguanil hydrochloride
>Tradename	>Generic Name

Last updated: July 30, 2025

Introduction

The ATC (Anatomical Therapeutic Chemical) classification system categorizes pharmacological agents into groups based on their therapeutic purpose and chemical characteristics. Class P01BB encompasses Biguanides, a class of oral antidiabetic agents mainly represented by metformin, which remains the cornerstone of type 2 diabetes mellitus (T2DM) management. This article provides an in-depth analysis of the market dynamics and patent landscape surrounding Biguanides (P01BB), offering critical insights into current trends, intellectual property trends, and future outlooks for stakeholders.

Market Overview of Biguanides (P01BB)

Current Market Size and Growth

Metformin, introduced in the 1950s and approved in numerous countries by the 1970s, remains the most prescribed oral hypoglycemic. The global market for Biguanides was valued approximately at USD 8 billion in 2022, driven by the rising prevalence of T2DM, especially in developing countries. The compound’s safety profile, cost-effectiveness, and extensive clinical evidence contribute to its dominance.

The overall market is projected to grow at a CAGR of 4-6% over the next five years, reaching an estimated USD 12 billion by 2028, as per industry reports (1). The increasing burden of T2DM in Asia-Pacific, Latin America, and Africa spurs demand for affordable and efficacious treatments, bolstering the Biguanide segment.

Market Drivers

Rising T2DM Prevalence: The International Diabetes Federation reports over 537 million adults diagnosed with diabetes globally, with projections exceeding 700 million by 2045 (2). This diabetes epidemic propels demand for first-line therapies like metformin.
Cost-Effectiveness: Metformin remains low-cost, accessible, and widely reimbursed across healthcare systems, especially in emerging markets.
Clinical Evidence and Guidelines: Extensive studies and clinical guidelines endorse metformin as the initial therapeutic agent for T2DM, reinforcing its market persistence.
New Formulations and Combinations: Innovations such as extended-release formulations and fixed-dose combinations with other antidiabetics like SGLT2 inhibitors and DPP-4 inhibitors expand market opportunities.

Market Challenges

Emerging Competition: New antidiabetic agents with novel mechanisms (e.g., GLP-1 receptor agonists, SGLT2 inhibitors) threaten the market share of traditional Biguanides, especially in advanced disease management (3).
Side Effect Profile: Gastrointestinal adverse effects, lactic acidosis risk, although rare, may limit use in some populations.
Patent Expirations: Many patents for innovative formulations are expiring, leading to increased generic competition, impacting profitability for innovator firms.

Patent Landscape of P01BB - Biguanides

Patent Trends and Timeline

The patent landscape for Biguanides exhibits a significant concentration of patent filings spanning from the 1950s to 2015. The initial patents focused on the synthesis and formulation of metformin, with subsequent patents targeting specific formulations, combinations, delivery mechanisms, and indications.

Key Patent Holders: Major pharmaceutical companies like Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and emerging players like AbbVie have historically protected their innovations through patents.
Patent Expirations: Many foundational patents related to metformin's chemical synthesis and immediate formulations expired between 2000 and 2015, leading to the proliferation of generic versions globally (4).
Recent Innovations: Post-2010, patent filings have shifted towards extended-release formulations, combination therapies, and novel delivery platforms, offering pathway exclusivity beyond first-generation patents.

Notable Patents and Patent Clusters

Formulation Patents: Extended-release formulations (e.g., Glumetza by Depomed) received patent protections extending exclusivity into the late 2020s, though many have faced patent challenges or expirations (5).
Combination Therapy Patents: Patents combining metformin with other antihyperglycemics, like sitagliptin or empagliflozin, have been filed to optimize treatment regimens, providing patentable innovations and potential market exclusivity.
Delivery Mechanisms: Novel delivery methods such as transdermal patches or nanoparticle encapsulations are emerging areas protected by recent patents to improve bioavailability and compliance (6).

Legal and Patent Challenges

Patent Litigations: Patent disputes often involve generic manufacturers challenging innovator patents, especially for formulations and combination therapies. For instance, prominent cases have delayed generic entry in certain markets.
Patent Strategy: Companies are increasingly leveraging "patent thickets"—multiple overlapping patents—to extend market exclusivity post-initial patent expirations.
Regulatory Impact: Patent protections influence market entry strategies, especially in countries with patent linkage policies.

Future Outlook and Innovation Trajectories

The Biguanide market is poised for incremental evolution.

New Formulations: Continued innovation around sustained-release and targeted delivery systems aims to enhance tolerability and adherence.
Combination Therapies: Patent-protected fixed-dose combinations (FDCs) with new agents may sustain patent exclusivity and market dominance.
Biosimilars and Generics: As patents for incremental innovations lapse, a wave of biosimilars and generics is expected, intensifying price competition.
Research and Development: Active research on Biguanides beyond glucose control, including their potential role in cancer and aging, presents new therapeutic avenues.

Conclusion

The landscape of ATC Class P01BB—Biguanides—remains vital amid evolving market dynamics. While patents for primary formulations have largely expired, innovation persists through new formulations, combination therapies, and delivery methods. Market growth is driven chiefly by global diabetes prevalence and socioeconomic factors enhancing access. Stakeholders must monitor patent expirations, emerging innovations, and competitive strategies to optimize positioning in this mature yet dynamically innovating class.

Key Takeaways

Market stability is sustained by metformin’s long-standing efficacy, safety, and affordability, with projections for steady growth aligned with diabetes prevalence.
Patent expirations for primary formulations have catalyzed a shift towards generic competition; however, innovation continues through formulation patents and combination therapies.
Developing regions present significant opportunity due to increasing disease burden and healthcare expansion, particularly where cost-effective therapies are prioritized.
Emerging formulations and delivery systems underpin incremental innovation, offering avenues for patent protection and market differentiation.
Strategic patent management and R&D are crucial for companies seeking competitive advantages in a landscape characterized by patent expirations and generic proliferation.

FAQs

1. What is the significance of patent expirations in the Biguanide market?
Patent expirations allow generic manufacturers to produce cost-effective versions, increasing market competition and reducing prices. This necessitates innovator companies to develop new formulations or combinations to maintain market share and patent protection.

2. Are there new Biguanide formulations under patent protection?
Yes. Extended-release forms, fixed-dose combinations with newer antidiabetics, and novel delivery mechanisms such as nanotechnology-based systems are actively patented, offering extended market exclusivity.

3. How does the patent landscape influence the availability of generic metformin?
Once primary patents expire, generic manufacturers can produce bioequivalent versions, improving access and affordability. Patent litigation and regulatory barriers can delay this process in certain jurisdictions.

4. What role do combination therapies play in the Biguanide patent landscape?
Combination therapies, especially those combining metformin with other agents like SGLT2 inhibitors, are protected by new patents, allowing innovation to extend market exclusivity while addressing unmet clinical needs.

5. How is innovation evolving beyond traditional formulations?
Research is exploring Biguanides' potential in areas like oncology and aging, and developing advanced delivery systems to improve tolerability and efficacy, which could lead to novel patents.

References

Grand View Research. Biguanides Market Size, Share & Trends Analysis Report. 2022.
International Diabetes Federation. IDF Diabetes Atlas, 10th Edition. 2021.
NCBI. Recent advancements in antidiabetic agents. 2022.
WIPO. Patent Landscape Reports on Biguanides. 2019.
Espacenet. Patent filings related to extended-release metformin formulations. 2023.
Worldwide. Espacenet. Innovations in drug delivery mechanisms for Biguanides. 2023.

Drugs in ATC Class P01BB

Drugs in ATC Class: P01BB - Biguanides

Market Dynamics and Patent Landscape for ATC Class P01BB - Biguanides